Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW597599B · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| GW597599B | DRUG | - |
| paroxetine | DRUG | - |
Inclusion Criteria: * Patients meet the diagnosis of Major Depressive Disorder (MDD). Exclusion Criteria: * Patients with a primary diagnosis other than MDD. * Patients with a history of schizophrenia, schizoaffective disorders, seizure disorders or bipolar affective disorder. * Patients receivin...
GW597599B is an investigational small molecule being studied for the treatment of Major Depressive Disorder. It is currently in Phase 2 clinical development, meaning it has not yet been approved by regulatory authorities and remains under investigation for safety and efficacy.
GW597599B is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical research to evaluate the drug's potential in treating Major Depressive Disorder.
GW597599B is in Phase 2 clinical development. It is an investigational drug, not yet approved by regulatory agencies. One Phase 2 trial has been completed, and the drug is not currently in active clinical trials.
GW597599B has been studied in one clinical trial, identified as NCT00048204. This was a Phase 2 study titled 'A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder,' which enrolled 372 participants and has been completed.
No, GW597599B is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Major Depressive Disorder. The drug has not completed the clinical trial process required for regulatory approval and remains under investigation.